{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.4015","meta":{"versionId":"5","lastUpdated":"2020-12-17T01:00:35.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4015","version":"20201217","name":"COVID19 ICD10PCS Value Set for Administration of Other Therapeutic Substance","status":"active","date":"2020-12-17T01:00:35-05:00","publisher":"Clinical Architecture","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","concept":[{"code":"XW013F5","display":"Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5"},{"code":"XW033F5","display":"Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5"},{"code":"XW043F5","display":"Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5"},{"code":"XW0DXF5","display":"Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5"}]}]}}